PBLA Panbela Therapeutics, Inc.

Panbela Therapeutics is a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer,

As of 11/26/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/02/2020
Outstanding shares:  13,434,152
Average volume:  71,242
Market cap:   $25,659,230
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    69833Q100
ISIN:        US69833Q1004
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.97
PS ratio:   0.00
Return on equity:   -55.45%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy